Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Buy
60
CFR Quote, Financials, Valuation and Earnings
Last price:
$123.74
Seasonality move
:
3.7%
Day range:
$123.48 - $125.85
52-week range:
$94.09 - $147.64
Dividend yield:
3.05%
P/E ratio:
13.95x
P/S ratio:
3.85x
P/B ratio:
2.12x
Volume:
230.8K
Avg. volume:
488.4K
1-year change:
11.15%
Market cap:
$7.9B
Revenue:
$2.1B
EPS (TTM):
$8.87
Analysts' Opinion
-
Consensus RatingCullen/Frost Bankers has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 8 Hold ratings, and 3 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $136.55, Cullen/Frost Bankers has an estimated upside of 10.36% from its current price of $123.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $114.00 representing 7.86% downside risk from its current price of $123.73.
Fair Value
-
According to the consensus of 12 analysts, Cullen/Frost Bankers has 10.36% upside to fair value with a price target of $136.55 per share.
CFR vs. S&P 500
-
Over the past 5 trading days, Cullen/Frost Bankers has overperformed the S&P 500 by 0.43% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cullen/Frost Bankers does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cullen/Frost Bankers has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Cullen/Frost Bankers reported revenues of $536.3M.
Earnings Growth
-
Cullen/Frost Bankers has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cullen/Frost Bankers reported earnings per share of $2.36.
Enterprise value:
-16.9B
EV / Invested capital:
-4.11x
Price / LTM sales:
3.85x
EV / EBIT:
-11.43x
EV / Revenue:
-8.21x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-19.66x
Price / Operating cash flow:
9.23x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
1.15%
Net Income Margin (TTM):
28.23%
Return On Equity:
15.29%
Return On Invested Capital:
14.44%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.7B | $2B | $2.1B | $502.1M | $536.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $8.81 | $9.10 | $8.87 | $1.55 | $2.36 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $20.7B | $30.5B | $30.3B | $25.3B | $25.3B | |
| Total Assets | $42.4B | $50.9B | $52.9B | $50.8B | $52.5B | |
| Current Liabilities | $2.1B | $2.8B | $4.7B | $4.1B | $4.4B | |
| Total Liabilities | $38.1B | $46.4B | $49.8B | $47.1B | $48.6B | |
| Total Equity | $4.3B | $4.4B | $3.1B | $3.7B | $3.9B | |
| Total Debt | $235.4M | $222.2M | $222.4M | $222.6M | $222.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $722.6M | $478.8M | $989.5M | -$83M | $64.3M | |
| Cash From Investing | -$8.3B | -$942.8M | -$180.9M | -$111.9M | -$294.4M | |
| Cash From Financing | $3B | -$2.9B | $738.3M | $1.3B | $1.3B | |
| Free Cash Flow | $620.1M | $320.2M | $861.8M | -$123.6M | $26.7M | |
CFR
Sector
Market Cap
$7.9B
$625.8M
Price % of 52-Week High
83.81%
86.55%
Dividend Yield
3.05%
1.95%
Shareholder Yield
3.49%
3.76%
1-Year Price Total Return
11.15%
9.43%
Beta (5-Year)
0.969
0.712
Dividend yield:
3.05%
Annualized payout:
$3.74
Payout ratio:
42.77%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$124.01
200-day SMA
Buy
Level
$122.49
Bollinger Bands (100)
Sell
Level
129.29 - 142.05
Chaikin Money Flow
Buy
Level
78.1M
20-day SMA
Sell
Level
$126.49
Relative Strength Index (RSI14)
Sell
Level
39.50
ADX Line
Sell
Level
28.27
Williams %R
Neutral
Level
-57.8301
50-day SMA
Sell
Level
$134.82
MACD (12, 26)
Sell
Level
-3.31
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8237)
Sell
CA Score
(Annual)
Level (-2.2784)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.0222)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
Stock Forecast FAQ
In the current month, CFR has received 1 Buy ratings 8 Hold ratings, and 3 Sell ratings. The CFR average analyst price target in the past 3 months is $136.55.
-
Where Will Cullen/Frost Bankers Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cullen/Frost Bankers share price will rise to $136.55 per share over the next 12 months.
-
What Do Analysts Say About Cullen/Frost Bankers?
Analysts are divided on their view about Cullen/Frost Bankers share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Cullen/Frost Bankers is a Buy and believe this share price will drop from its current level to $164.00.
-
What Is Cullen/Frost Bankers's Price Target?
The price target for Cullen/Frost Bankers over the next 1-year time period is forecast to be $136.55 according to 12 Wall Street analysts, 1 of them rates the stock a Buy, 3 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is CFR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cullen/Frost Bankers is a Hold. 8 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CFR?
You can purchase shares of Cullen/Frost Bankers via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cullen/Frost Bankers shares.
-
What Is The Cullen/Frost Bankers Share Price Today?
Cullen/Frost Bankers was last trading at $123.74 per share. This represents the most recent stock quote for Cullen/Frost Bankers. Yesterday, Cullen/Frost Bankers closed at $123.73 per share.
-
How To Buy Cullen/Frost Bankers Stock Online?
In order to purchase Cullen/Frost Bankers stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Signet Jewelers Stock Go Up So Much?
Signet Jewelers (NYSE:SIG) is the largest diamond retailer in the…
Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
69
CNXC alert for Mar 28
Concentrix [CNXC] is down 11.29% over the past day.
Buy
74
SLNO alert for Mar 28
Soleno Therapeutics [SLNO] is up 7.15% over the past day.
Buy
51
CAR alert for Mar 28
Avis Budget Group [CAR] is down 0.28% over the past day.
